A 2027 rebound with the regulatory cloud lifted
- The main thesis is a 2027 recovery after a hard 2025 and a 2026 reset year.
- Management raised 2026 adjusted EPS guidance to at least $27 after Q2, setting a solid baseline.
- The CMS risk adjustment sanctions threat was fully resolved in July 2026, removing a major overhang.
- Elevance is actively exiting unprofitable Medicaid markets, starting with Washington D.C., to protect margins.
- Medicare Advantage membership is shrinking as Elevance cuts less profitable plans to reach a 2% margin.
The rebound needs clean execution
Elevance is firmly a 2027 recovery story. The company had to reset earnings expectations in 2025 because medical costs rose faster than expected in ACA and Medicaid plans. Management now treats 2026 as a year of execution, which means the company is shrinking weak business, raising prices where possible, and rebuilding margins.
The bull case is strengthening. The major regulatory overhang from CMS was fully resolved in July 2026, closing the matter without sanctions. With that distraction gone, management raised 2026 adjusted EPS guidance to at least $27. The Medicare Advantage pullback is painful but planned, and management says it remains on track for a 2% margin in 2026. If Medicaid margins bottom out as expected, Carelon can help push adjusted EPS growth to at least 12% in 2027.
The bear case centers on Medicaid rates and execution. Medicaid cost trends remain high. To protect margins, Elevance is proactively exiting markets, starting with Washington D.C., and evaluating others. If state rate updates do not cover rising medical costs, the margin recovery timeline could slip and top line revenue could fall faster than expected.
Premiums first, Carelon as the flywheel
Most of Elevance's money starts with health insurance premiums. It covers Commercial, Medicare, and Medicaid members. The key job is pricing plans so premiums cover medical claims, while still staying competitive. If claims rise faster than prices, margins fall quickly.
Carelon is the second engine. CarelonRx manages pharmacy benefits, specialty pharmacy, formularies, rebates, claims, and home delivery. Carelon Services adds clinical and operating services such as behavioral health and home and community-based care. These services support Elevance's own insurance plans and also serve outside customers.
This structure can work well when the parts help each other. Carelon can lower costs for the insurance side and earn service revenue at the same time. The weak spot is that Carelon still feels pressure when Elevance's own health plan membership falls. Carelon must secure large external wins to offset any internal membership declines.
What Elevance sells
Commercial health plans
These include employer plans and individual ACA exchange plans. ACA is a focus area because member illness levels and medical costs rose across the market.
Medicaid managed care
Elevance manages care for low-income members through state contracts. Management expects a negative 1.75% trough margin in 2026 and is exiting unprofitable markets to recover.
Medicare Advantage
These plans serve seniors. Elevance is cutting less profitable membership to rebuild margins, with a goal of reaching a 2% margin in 2026.
CarelonRx
CarelonRx is Elevance's pharmacy benefit manager. It handles scripts, specialty pharmacy, rebates, networks, and related pharmacy services for Elevance plans and outside customers.
Carelon Services
Carelon Services provides care management, behavioral health, and home and community-based services. It is the services growth engine, though lower internal membership can slow reported growth.
Federal Employee Program and other benefits
Elevance also serves federal employee and ancillary benefit markets such as dental and vision. These add scale but are not the main swing factor in the 2027 recovery thesis.
First half 2026 segment mix
Shares reflect gross reportable segment operating revenue before eliminations and excluding Corporate and Other. Health Benefits remains the largest segment, while Carelon relies partly on internal revenue.
What could break the rebound
Medicaid rates keep lagging costs
High impact · Medium oddsMedicaid cost trends remain high because members are using more care and have higher acuity. Management expects 2026 to be the trough year with a negative 1.75% margin. If state rate updates do not catch up, the 2027 recovery could slip.
Market exits reduce scale
Medium impact · High oddsElevance is exiting the Washington D.C. Medicaid market and expects to exit more markets over the next 12 to 18 months. While this protects margins, it shrinks membership and could hurt top line revenue growth.
ACA medical costs stay too high
Medium impact · Medium oddsACA profitability worsened after membership shifts and lower effectuation rates changed the risk pool. Elevance can raise prices, but regulators, competitors, and customer behavior limit how fast it can react.
Carelon cannot offset shrinking membership
Medium impact · Medium oddsCarelon is central to the growth story, but it still depends partly on Elevance's own health plan members. With Elevance shrinking Medicare and Medicaid enrollment, external wins must be large enough to offset internal pressure.
In one breath
Why did Elevance Health cut Medicare Advantage membership?
Management is exiting or reshaping less profitable Medicare Advantage business. The deliberate membership losses are designed to yield a 2% margin target in 2026.
What is Carelon?
Carelon is Elevance's healthcare services platform. It includes CarelonRx for pharmacy benefit management and Carelon Services for care management, behavioral health, and other clinical services.
Are the CMS sanctions still a risk?
No. Elevance confirmed in July 2026 that it completed all steps required by CMS. The agency confirmed that sanctions will not be imposed and the matter is closed.
Why is 2027 important for Elevance?
Management expects at least 12% adjusted EPS growth in 2027 from a $27 baseline in 2026. That depends on Medicaid bottoming, Medicare Advantage improving, and Carelon continuing to grow.
